78628-28-1

78628-28-1 structure

Name: Roxane
Chemical Name: [2-oxo-2-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]ethyl] acetate
CAS Number: 78628-28-1
Molecular Formula: C₁₉H₂₈N₂O₄
Molecular Weight: 348.437
Catalog: API Antiallergic Antihistamine
Create Date: 2018-10-03 17:47:33
Modify Date: 2024-01-09 15:59:33
Roxatidine acetate is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine acetate has antisecretory potency against gastric acid secretion. Roxatidine acetate can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine acetate has antitumor activity[1][2][3].

Name	[2-oxo-2-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]ethyl] acetate
Synonyms	Roxatidine acetate Roxatidinum [Latin] Pifatidine Xarcin 2-Oxo-2-({3-[3-(1-piperidinylmethyl)phenoxy]propyl}amino)ethyl acetate ACETAMIDE, 2-HYDROXY-N-(3-(m-(PIPERIDINOMETHYL)PHENOXY)PROPYL)-, ACETATE (ester) Roxit Gastralgin Acetamide, 2-(acetyloxy)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]- Roxatidina Roxatidinum 2-(Acetyloxy)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]acetamide 2-Oxo-2-({3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}amino)ethylacetat 2-(Acetyloxy)-N-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)acetamide Altat Roxatidina [Spanish] MFCD00866898 Roxane 2-Oxo-2-({3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}amino)ethyl acetate Aceroxatidine

Description	Roxatidine acetate is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine acetate has antisecretory potency against gastric acid secretion. Roxatidine acetate can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine acetate has antitumor activity[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Inflammation/Immunology Research Areas >> Metabolic Disease Signaling Pathways >> GPCR/G Protein >> Histamine Receptor
Target	H2 Receptor
In Vitro	Roxatidine acetate (0-120 μM, 1 h) suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages[2]. Roxatidine acetate (6.25 μM, 12.5 μM, and 25 μM; pre-treatment for 30 min) suppresses the PMACI-induced activation of p38 MAPK, but does not affect the phosphorylation of ERK or JNK. The total ERK 1/2, JNK, and p38 MAPK levels are unaffected by roxatidine in human mast-cells-1 (HMC-1) cells[4]. Western Blot Analysis[2] Cell Line: RAW 264.7 Concentration: 40, 80, and 120 μM Incubation Time: 1 h Result: Suppressed LPS-induced PGE2, NO, and histamine production and COX-2, iNOS, and HDC expressions. Inhibited expressions of TNF-α, IL-1β, IL-6, and VEGF-1. Concentration-dependently attenuated the nuclear translocations of p65 and p50. Inhibited LPS-induced phosphorylation of p38 MAP kinase. Significantly down-regulated the LPS-induced productions of NO and PGE2 (prostaglandin E2).
In Vivo	Roxatidine acetate (0-300 mg/kg; p.o.; 26 days) suppressed growth of Colon 38 tumor implants in mice[3]. Roxatidine acetate (oral gavage; 20 mg/kg; single dose) inhibits Compound 48/80-increased TNF-α, IL-6, and IL-1β production and mRNA expression. Additionally, Roxatidine decreases the compound 48/80-induced degradation of procaspase-1 and appearance of the corresponding cleaved bands in mice[4]. Animal Model: Male C57BL/6 Colon 38-bearing mice (8-week-old, 20 – 22 g)[3] Dosage: 30, 100, and 300 mg/kg per day, 1 ml/100 g body weight Administration: Oral administration, 29 days beginning 3 days before Colon 38 implantation or 26 days beginning concomitantly with Colon 38 implantation Result: Suppressed growth of Colon 38 tumor implants in a dose-related manner after day 26. Suppressed VEGF levels in tumor tissue and significantly decreased serum VEGF levels. Animal Model: ICR male mice (6 weeks old)[4] Dosage: 20 mg/kg Administration: Oral gavage; 20 mg/kg; single dose Result: Suppressed compound 48/80-induced allergic inflammation in anaphylactic animal model.
References	[1]. Murdoch D, et al. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. Drugs. 1991 Aug;42(2):240-60. [2]. Cho EJ, et al. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem. 2011 Dec;112(12):3648-59. [3]. Tomita K, et al. Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci. 2003 Nov;93(3):321-30. [4]. Minho Lee, et al. Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation. Sci Rep. 2017 Jan 31;7:41721.

Density	1.1±0.1 g/cm3
Boiling Point	537.3±45.0 °C at 760 mmHg
Melting Point	225 °C (dec.)(lit.)
Molecular Formula	C₁₉H₂₈N₂O₄
Molecular Weight	348.437
Flash Point	278.7±28.7 °C
Exact Mass	348.204895
PSA	67.87000
LogP	2.00
Vapour Pressure	0.0±1.4 mmHg at 25°C
Index of Refraction	1.533

CHEMICAL IDENTIFICATION

RTECS NUMBER :: AB4249200

CHEMICAL NAME :: Acetamide, 2-(acetyloxy)-N-(3-(3-(1-piperidinylmethyl)phenoxy)pr opyl)-

CAS REGISTRY NUMBER :: 78628-28-1

LAST UPDATED :: 199612

DATA ITEMS CITED :: 1

MOLECULAR FORMULA :: C19-H28-N2-O4

MOLECULAR WEIGHT :: 348.49

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4293557

Hazard Codes	Xn,Xi
Risk Phrases	R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases	S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . S36:Wear suitable protective clothing . S37/39:Wear suitable gloves and eye/face protection .
WGK Germany	3
RTECS	HA1595000
HS Code	2933399090

HS Code	2933399090
Summary	2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

1533431-90-1	1158522-08-7
940364-43-2	2288623-47-0
134104-43-1	131615-57-1
1379351-59-3	22324-86-3
6906-52-1	930439-75-1